TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure.

Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD, De Carvalho DD. · 2018

Read TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. by Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD, De Carvalho DD. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6224529.txt.

Introduction

Chakravarthy and co-authors found a gene pattern that links stroma to immune escape. The matrix around tumours shapes cancer course. Support cells called fibroblasts build much of that matrix. The study ran a large pan-cancer analysis. It appeared in Nature Communications.

The team defined a set of matrix genes switched on in cancer. High levels linked to worse prognosis. The pattern tied to TGF-b signalling in fibroblasts. Tumours with it suppressed immune activity. They also carried distinct mutations, such as BRAF and TP53. The pattern predicted failure of PD-1 blockade therapy. It beat earlier proposed markers at that task. The authors suggest TGF-b blockade could help. That idea still needs preclinical testing.

Catalog record

CREATORChakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD, De Carvalho DD.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6224529

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure By Ankur Chakravarthy, Lubaba Khan, Nathan Peter Bensler, Pinaki Bose, Daniel D De Carvalho Published in: Nature Communications DOI: 10.1038/s41467-018-06654-8 ABSTRACT Abstract The extracellular matrix (ECM) is a key determinant of cancer progression and prognosis. Here we report findings from one of the largest pan-cancer analyses of ECM gene dysregulation in cancer. We define a distinct set of ECM genes upregulated in cancer (C-ECM) and linked to worse prognosis. We found that the C-ECM transcriptional programme dysregulation is correlated with the activation of TGF-β signalling in cancer-associated fibroblasts and is linked to immunosuppression in otherwise immunologically active tumours. Cancers that activate this programme carry distinct genomic profiles, such as BRAF, SMAD4 and TP53 mutations and MYC amplification. Finally, we show that this signature is a predictor of the failure of PD-1 blockade and outperforms previously-proposed biomarkers. Thus, our findings identify a distinct transcriptional pattern of ECM genes in operation across cancers that may be potentially targeted, pending preclinical validation, using TGF-β blockade to enhance responses to immune-checkpoint blockade. INTRODUCTION The ability to disseminate, invade and successfully colonise other tissues is a critical hallmark of cancer that involves remodelling of the extracellular matrix (ECM) laid down by fibroblasts1. Moreover, cancer-associated fibroblasts (CAFs) produce key growth factors and cytokines as components of the ECM that fuel tumour growth, metastasis and chemoresistance and immune response2–4. Further, ECM changes also predict prognosis in pancreatic5 and colorectal cancers6,7. Here we examine the pan-cancer landscape of ECM gene dysregulation and find that a subset of ECM genes is dysregulated specifically in cancer and is enriched among transcriptional changes that distinguish normal from malignant tissue. We further show that the high expression of this subset of genes is adversely prognostic in pan-cancer analyses. Then, using deconvolution and analyses of transcriptional profiles from dissociated tumour fractions, we show that these genes are modulated in CAFs. Subsequently, based on multiplatform analysis of The Cancer Genome Atlas (TCGA) data, we correlated these profiles to transforming growth factor (TGF)-β signalling in the tumour microenvironment and show that this transcriptional programme is enriched in immunologically active cancers, suggesting a possible role in immune evasion/adaptation. Finally, we demonstrate that this transcriptional programme predicts responses to immune checkpoint blockade better than mutation burden8, cytolytic activity (CYT)9, TGF-β expression alone, a CAF signature10 or a T cell-inflamed signature11. We have thus identified a novel signature of immune evasion that is a potential target for pharmacological modulation and may facilitate effective patient stratification in precision immunotherapy, pending preclinical validation. RESULTS Definition of a pan-cancer ECM dysregulation profile Initially, to study ECM gene dysregulation across cancers, we defined a transcriptional signature to distinguish malignant (n = 8043) and normal tissues (n = 704) accounting for tumour type (n = 15) from TCGA and tested for enrichment of an ECM-associated gene-set we curated based on gene ontology terms (Supplementary Table 1, Supplementary Figure 1A). We were motivated to define such a pan-cancer signature given the wide variability of ECM gene transcription per se across tissue types (Supplementary Figure 1B). This identified 58 out of the 249 ECM genes represented in the RNA-seq data set to be cancer associated (from hereon referred to as cancer-associated ECM genes (C-ECM genes)) (Supplementary Table 2), comprising 30 out of the 522 upregulated genes, and 28 out of the 644 downregulated genes, representing significant enrichment among both upregulated (odds ratio (OR) = 3.51, p < 3.9e−8, Fisher’s Exact Test, two-sided) and downregulated (OR = 2.57, p = 3e−5, Fisher’s Exact Test) genes in malignant tissues (Fig. 1a). These C-ECM genes showed generally high correlations and clustering the Pearson correlation matrix of intergene correlations across TCGA cancers segregated them into generally distinct blocks of upregulated and downregulated genes (Supplementary Figure 1C, two sided), suggesting co-regulation. [Figure: ECM genes are significantly associated with tumorigenesis and prognosis. a Volcano plot showing fold changes for genes differentially expressed between cancer and normal samples. ECM genes are enriched in upregulated and downregulated genes. b Boxplots of C-ECM-up enrichment scores show variation across tumour types (n = 9716, see S1F for C-ECM-down genes). c Plot of Cox model coefficients by quartile for C-ECM-up and -down scores pan-cancer, error bars indicate 95% confidence intervals (n = 6128). d Unadjusted Kaplan–Meier curves showing survival by C-ECM-up-quartile., asterisks indicate statistical significance. ***p < 0.001. On the volcano plot, y axis = −log10 fold change, x axis = test statistic/fold change/Spearman’s Rho. On volcano plots, all enrichment statistics are from Fisher’s Exact Tests] Notably, 48 out of the 58 of these genes were also implicated in a previous proteomics-based approach to define a cancer matrisome12 and we further validated our signature at the proteomic level by examining transcript–protein correlations using matched BRCA samples from CPTAC13, wherein mostly positive correlations were observed for 37 out of the 49 C-ECM genes covered by both mass spectrometry and RNA-seq (Supplementary Figure 1D). Analysis using the CPTAC ovarian cancer data set also yielded similar correlations, with the caveat that only 24 C-ECM genes were represented in the mass spectrometric data set (Supplementary Figure 1E)14. Upon summarisation using ssGSEA (single sample Gene Set Enrichment Analysis) scores15,16, these C-ECM genes show broad variation across tumour types (Fig. 1b, Supplementary Figure 1B,F). We then performed a Cox regression based on quartile-thresholded C-ECM scores with American Joint Committee on Cancer stage and tumour type as strata to examine the prognostic impact of this dysregulation; upregulated C-ECM genes were significantly associated with poor prognosis (Fig. 1c, d, hazard ratio (HR) = 1.73, p < 6.3e−7 for top versus bottom quartile, Cox regression, two sided) while downregulated C-ECM genes were not (Supplementary Figure 1G), suggesting that the variation we observed in C-ECM gene transcription is clinically relevant. We also tested for the independent prognostic capability of C-ECM genes by repeating this regression with non-ECM upregulated and downregulated gene score quartiles included as covariates and found that C-ECM-up scores were still prognostic (HR = 1.41, p = 0.003 for top versus bottom quartile, full model coefficients in Supplementary Table 3, Cox regression, two sided). We also performed survival analyses where the quartiles of up-and-down scores were combined into single categories. This showed that cancers with the highest quartile of the up-score (Q4) and the lowest quartile of the down-score (Q1) had markedly increased risk of death (Supplementary Figure 1H, HR = 3.18, p < 8.5e−5, Cox regression, two-sided). C-ECM dysregulation is associated with the presence of CAFs Given the previously identified role of distinct stromal cells in determining the composition and behaviour of the ECM17, we then attempted to infer the potential cell types associated with C-ECM transcriptional variation. Using a range of computational approaches, we examined whether changes in cellular composition, along with cell-type-specific transcriptional changes, could be associated with C-ECM gene dysregulation and found multiple indicators that C-ECM gene dysregulation originated in CAFs. First, we sought to estimate whether there was a cancer-specific contribution to the C-ECM signature by examining correlations between C-ECM scores and tumour purity. This was motivated by the reasoning that if the C-ECM signature originated in the tumour epithelial compartment it would be positively associated with tumour cellularity. We found tumour purity estimated using ABSOLUTE,

Read the complete text